CoChat

A Novel Combination Treatment Targeting BCL-XL and MCL1 for KRAS/BRAF -mutated and BCL2L1 -amplified Colorectal Cancers

Published version of a preprint

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

Colorectal cancer is the third most commonly diagnosed cancer in the world, and exhibits heterogeneous characteristics in terms of genomic alterations, expression signature, and drug responsiveness. Although there have been considerable efforts to classify this disease based on high-throughput sequencing techniques, targeted treatments for specific subgroups have been limited. KRAS and BRAF mutations are prevalent genetic alterations in colorectal cancers, and patients with mutations in either of these genes have a worse prognosis and are resistant to anti-EGFR treatments. In this study, we have found that a subgroup of colorectal cancers, defined by having either KRAS or BRAF (KRAS/BRAF) mutations and BCL2L1 (encoding BCL-XL) amplification, can be effectively targeted by simultaneous inhibition of BCL-XL (with ABT-263) and MCL1 (with YM-155). This combination treatment of ABT-263 and YM-155 was shown to have a synergistic effect in vitro as well as in in vivo patient-derived xenograft models. Our data suggest that combined inhibition of BCL-XL and MCL1 provides a promising treatment strategy for this genomically defined colorectal cancer subgroup. Mol Cancer Ther; 16(10); 2178–90. ©2017 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-16-0735

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 50 references

Cited by

See all 24

Metadata

Authors
Cho, S.-Y., Han, J. Y., Na, D., Kang, W., Lee, A., Kim, J., Lee, J., Min, S., Kang, J., Chae, J., Kim, J.-I., Park, H., Lee, W.-S., & Lee, C.
Affiliations
  • Ewha Womans University (KR)
  • Seoul National University (KR)
  • Gwangju Institute of Science and Technology (KR)
  • Gachon University (KR)
Venue
Molecular Cancer Therapeutics
Published
2017-10-01
Volume
16
Issue
10
Pages
2178-2190
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2625289674
Cited by
24
References
50
Citations by year
2025: 2 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 11 · 2019: 3
FWCI
1.24
Type
journal article
Language
en
Open access
closed
Locations
  • Molecular Cancer Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
  • The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
  • Seoul National University Open Repository (Seoul National University) (submittedVersion)
Funders
National Cancer Institute (P30CA034196)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Keywords
colorectal cancer, KRAS mutation, BRAF mutation, Bcl-xL, Mcl-1, navitoclax, combination therapy, apoptosis inhibition, patient-derived xenografts, anti-EGFR resistance, drug synergy
MeSH terms
Aged, Aniline Compounds, Animals, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Imidazoles, Mutation, Naphthoquinones, Sulfonamides, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Xenograft Model Antitumor Assays, Cell Line, Tumor, Proto-Oncogene Proteins B-raf, bcl-X Protein, Mice, Myeloid Cell Leukemia Sequence 1 Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Novel Combination Treatment Targeting BCL-XL and MCL1 for KRAS/BRAF -mutated and BCL2L1 -amplified Colorectal Cancers. https://app.cochat.ai/papers/10.1158/1535-7163.mct-16-0735
The paper
Cho, S.-Y., Han, J. Y., Na, D., Kang, W., Lee, A., Kim, J., Lee, J., Min, S., Kang, J., Chae, J., Kim, J.-I., Park, H., Lee, W.-S., & Lee, C. (2017). A Novel Combination Treatment Targeting BCL-XL and MCL1 for KRAS/BRAF -mutated and BCL2L1 -amplified Colorectal Cancers. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-16-0735

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.